Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Streptococcus Agalactiae Infection

Tundra lists 3 Streptococcus Agalactiae Infection clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07922226

A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial

The main objective of the Phase 2 part of the trial is to assess the immunogenicity of GBS-NN/NN2 vaccine at birth in infant participants and to determine the occurrence of serious adverse events (SAEs) and adverse event of special interest (AESIs) after GBS-NN/NN2 vaccine administration compared to placebo, in both maternal and infant participants. The main objective of the Phase 3 part of the trial is to assess the ability of GBS-NN/NN2 vaccine to induce functional antibody titres protective against invasive GBS (iGBS) early-onset disease (EoD) in infant participants, to assess the ability of GBS-NN/NN2 vaccine to induce functional antibody titres protective against iGBS late-onset disease (LoD) in infant participants and to determine the occurrence of SAEs and AESIs after GBS-NN/NN2 vaccine administration compared to placebo, in both maternal and infant participants.

Gender: FEMALE

Ages: 18 Years - 49 Years

Updated: 2026-11-06

Streptococcus Agalactiae Infection
Neonatal Sepsis
Pneumonia
+2
WITHDRAWN

NCT06494475

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

The main objectives of the study are to demonstrate the non-inferiority of the immune response induced by co administered GBS-NN/NN2 and tetanus, diphtheria, and acellular pertussis (Tdap) compared to the separate administration of GBS-NN/NN2 and Tdap, to evaluate the reactogenicity of GBS NN/NN2 when administered alone or in combination with Tdap, and to evaluate the safety of GBS-NN/NN2 when administered alone or in combination with Tdap in terms of serious adverse events (SAEs) and unsolicited adverse events (AEs).

Gender: FEMALE

Ages: 18 Years - 49 Years

Updated: 2026-10-13

Streptococcus Agalactiae Infection
ACTIVE NOT RECRUITING

NCT06592586

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

The main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccination with GBS-NN/NN2 in all participants.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-09-04

5 states

Streptococcus Agalactiae Infection
Neonatal Sepsis
Pneumonia
+6